Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors

Increasing HPV Vaccination Coverage Among Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors: A Multilevel Intervention

The primary objectives of this study are to increase HPV vaccination initiation and 3-dose completion among pediatric, adolescent, and young adult (PAYA) cancer survivors

Study Overview

• Status: Active, not recruiting
• Conditions: Cancer; HPV Associated Cancer
• Intervention / Treatment: Behavioral: GLAm app

Detailed Description

PAYA cancer survivors are 2.8 times more likely to develop a secondary human papillomavirus (HPV)-associated cancer than the general population. Unfortunately, HPV vaccination coverage among PAYA cancer survivors is even lower than that in the general population. Provision of adequate vaccine information and instructions for timing of vaccination post-treatment is associated with an increased intention to vaccinate. Nonetheless, research show a minority of cancer care teams specifically discuss HPV vaccination with PAYA cancer survivors and their caregivers. The purpose of this study is to test the efficacy of an oncologist- and clinic-level intervention and the additional effect of a patient-level app-based intervention to improve initiation and 3-dose completion of the HPV vaccine series.

• Study Type: Interventional
• Enrollment (Actual): 162
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • University of Minnesota Masonic Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 9 years to 26 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Current patient in the University of Minnesota CCSP clinic or the Children's Minnesota Long-Term Follow-up (LTFU) Program clinic.
• Patients seen in the CCSP clinic who do not have a history of cancer but who have received immunosuppressive therapy or HSCT for treatment of a hematologic disorder.
• Survivor of childhood cancer (defined as diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age.
• 6+ months post-treatment; current treatment for graft-versus-host disease allowed
• No previous HPV vaccination or incomplete HPV vaccination (defined as <3 doses post-cancer therapy). Individuals who are unsure of their HPV vaccination status who are unable to find vaccination records per the procedures detailed in Section 5.2, EHR support will be eligible, in concordance with real-world clinical practice regarding HPV vaccination.

Exclusion Criteria:

• Previous completion of the HPV vaccination series. Those who are eligible for re-vaccination per the CDC guidelines will be encouraged by their oncologist to re-vaccinate, but will not be included in the QI study or RCT.
• Unable to read/write in English per self-report (only applies to participants in the RCT [Aim 2]).
• Pregnant at the time of enrollment or plans to become pregnant in the next year. Pregnancy test at the time of enrollment is not required if pregnancy not clinically suspected in concordance with clinical guidelines for HPV vaccine administration.
• Currently receiving treatment for cancer or hematologic disorder or plan for treatment within 12 months of enrollment; treatment for graft-versus-host disease allowed.
• Other contraindications to the HPV vaccine (e.g. history of immediate hypersensitivity reaction to any vaccine component, including yeast).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GLAm App; Participants will have access to Game based Learning Avatar navigated mobile (GLAm ) app and will receive the receive the quality improvement (QI) intervention plus the GLAm app.	Behavioral: GLAm app; Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
No Intervention: Usual care; Participants in the control group will not receive the access to the GLAm app. They will receive the quality improvement (QI) intervention only.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study enrollment	Number of participants who complete the 3-dose HPV vaccine series within 12 months of study enrollment.	within 6 months of index clinic visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in HPV and HPV vaccination knowledge pre- and post-intervention	The change in knowledge is assessed through self reported surveys administered to participants	baseline and 1 year post survivorship clinic visit
Number of participants intent to vaccinate against HPV	The number of participants with intent to vaccinate is assessed through self reported surveys administered to participants	At the time of index clinic visit, baseline
Proportion of participants intending to vaccinate initiating and completing the vaccine series	The Proportion of participants intending to vaccinate initiating and completing the vaccine series is measured through surveys and health record review	1 year post index clinic visit
Demographics differences associated with vaccination status	measure through health record review	1 year post index clinic visit
Cancer occurrences associated with vaccination status	measure through health record review	1 year post index clinic visit
Treatment differences associated with vaccination status	measure through health record review	1 year post index clinic visit
Number of participants experiencing barriers to vaccination	Survey measurement	1 year post index clinic visit
Number of participants using and accepting the game based learning app	Survey measurement	1 year post index clinic visit
Concordance between reported and documented vaccination against HPV	measured through surveys and health record review	1 year post index clinic visit

Collaborators and Investigators

• Sponsor: Masonic Cancer Center, University of Minnesota
• Investigators: Principal Investigator: Deanna Teoh, MD, MS, Masonic Cancer Center, University of Minnesota

Study record dates

Study Major Dates

• Study Start (Actual): July 24, 2023
• Primary Completion (Actual): August 15, 2025
• Study Completion (Estimated): August 1, 2026

Study Registration Dates

• First Submitted: December 19, 2022
• First Submitted That Met QC Criteria: December 19, 2022
• First Posted (Actual): December 27, 2022

Study Record Updates

• Last Update Posted (Actual): August 22, 2025
• Last Update Submitted That Met QC Criteria: August 21, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: HPV vaccine
• Other Study ID Numbers: 2021LS099

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: At the end of the study, the link between subjects' identifiable identification codes and their identifiable information will be destroyed per the AHC protocol at the time of data disposal. The original data records will be archived for 7 years (in accordance with data practices).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No